Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Inclusion Criteria: 1. Patients diagnosed with MCI due to AD according to DSM-V 2. Age between 50 and 80 years (male and female) 3. MMSE score 22-30 4. Written informed consent (according AMG §40 (1) 3b) 5. Level of Aβ-oligomers: mind. 1fM 6. CSF according to diagnosis (p-tau \> 62 pg/ml, total CSF Aβ 1-42/1-40 ratio ≤ 0.055) 7. 3 months prior to screening stable medication 8. Females without childbearing potential Exclusion Criteria: 1. History of seizures 2. History of stroke or TIA 3. Unstable medical, neurological or psychiatric condition 4. Current treatment with one of the following substances: * Typical antipsychotic or neuroleptic medication within 6 months of screening * Anti-coagulation medications within 3 months of screening * Chronic use of opiates or opioids (including long-acting opioid medication) within 3 months of screening * Stimulant medications (amphetamine, methylphenidate preparations, or modafinil) within 1 month of screening and throughout the study * Chronic use of benzodiazepines, barbiturates, or hypnotics from 3 months before screening 5. Persons who are legally detained in an official institution 6. Persons who may be dependent on the sponsor, the investigator or the trial site 7. Persons without caregiver 8. Participation in other clinical trials according to AMG (1 month before the time of this trial) 9. Persons showing EEG abnormalities